These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31714657)

  • 1. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
    Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
    J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
    Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
    J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
    Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy.
    Ansari AS; K C R; Jiang X; Uludaǧ H
    J Biomed Mater Res A; 2021 Nov; 109(11):2306-2321. PubMed ID: 33964112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
    Vysochinskaya V; Zabrodskaya Y; Dovbysh O; Emelyanov A; Klimenko V; Knyazev N; Terterov I; Egorova M; Bogdanov A; Maslov M; Vasin A; Dubina M
    Biochimie; 2024 Jun; 221():1-12. PubMed ID: 38215931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
    Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
    Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.
    Ansari AS; K C R; Morales LC; Nasrullah M; Meenakshi Sundaram DN; Kucharski C; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2024 Mar; 367():821-836. PubMed ID: 38360178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
    Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
    Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
    Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
    Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).
    Mohseni M; Kucharski C; K C RB; Nasrullah M; Jiang X; Uludağ H; Brandwein J
    PLoS One; 2021; 16(6):e0251719. PubMed ID: 34157051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibronectin-modified surfaces for evaluating the influence of cell adhesion on sensitivity of leukemic cells to siRNA nanoparticles.
    Valencia-Serna J; Chevallier P; Kc RB; Laroche G; Uludağ H
    Nanomedicine (Lond); 2016 May; 11(9):1123-38. PubMed ID: 27074102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates.
    Shinkai Y; Kashihara S; Minematsu G; Fujii H; Naemura M; Kotake Y; Morita Y; Ohnuki K; Fokina AA; Stetsenko DA; Filichev VV; Fujii M
    Nucleic Acid Ther; 2017 Jun; 27(3):168-175. PubMed ID: 28355131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.
    Aliabadi HM; Bahadur K C R; Bousoik E; Hall R; Barbarino A; Thapa B; Coyle M; Mahdipoor P; Uludağ H
    Acta Biomater; 2020 Jan; 102():351-366. PubMed ID: 31760224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.